新闻中心
Russian Academy of Engineering Foreign Academician Dr. Zhang Dan was Invited to Visit and Guide Clinical Trials
Source: | Author:开悦生命 | Published time: 2024-10-25 | 428 Views | Share:

On October 20th, 2024, KeYe Biotech had the honor of welcoming Academician Dr. Zhang Dan, who took time from his busy schedule to visit Shenzhen and attend a meeting with the company. Dr. Zhang Dan personally visited KeYe Biotech and engaged in valuable discussions with the clinical team, offering his expert guidance on ongoing clinical research.

Dr. Zhang Dan, a foreign academician of the Russian Academy of Engineering, has a rich and diverse academic and professional background. He studied at Peking University’s Department of Biology from 1981 to 1984, and then at Peking Union Medical College from 1984 to 1989, where he earned a Doctor of Medicine degree. Subsequently, he pursued advanced studies at prestigious institutions, including Harvard University's School of Public Health and the Wharton School of the University of Pennsylvania, gaining a Master of Public Health, a Master of Hospital Management, and currently working towards a Doctorate in Finance. Dr. Zhang has an extensive background in clinical medicine, pharmacy, and medical testing, along with a broad international perspective and rich experience in global clinical trials. He played a key role in developing ICH standards and led clinical development and drug safety evaluations for Sigma-Tau in Italy for the North American market. Dr. Zhang is also the founder of Fountain Medical Development Ltd. and was the first Chairman of Quintiles Transnational Corporation's Greater China region, where he successfully established and expanded its market presence.

During his visit, Dr. Zhang was briefed on the progress of KeYe Biotech's clinical research and offered valuable recommendations on clinical trial design, regulatory filing pathways, and communication strategies with regulatory authorities. Most importantly, he emphasized the significance of maintaining high-quality control standards throughout the clinical trial process, particularly from an international perspective.

KeYe Biotech’s founder and Chief Scientific Officer, Dr. Yandong Zhang, along with the company's Medical Director, Ms. Xuemei Tang, participated in the discussions. KeYe Biotech is deeply grateful for the guidance and support provided by such esteemed individuals who have helped shape the company's growth and success.